Jeffrey Leiden
Principal executive officer pay for Jeffrey Leiden, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
VERTEX PHARMACEUTICALS INC / MA (VRTX) FY2018–FY2020
Lagged peersTSR -2% vs peer group 39% over FY2018–FY2020
Paid for declineCAP $27,646,261→$31,319,824 while $100 invested went $110.58→$107.94 (FY2018–FY2020)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2018 | $18.8M | $27.6M |
| FY2019 | $18.8M | $37.1M |
| FY2020 | $16.5M | $31.3M |
The company's "$100 invested" index ran $110.58 at FY2018 → $107.94 by FY2020 — an annualized return of -1.2%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: -1.2%/yr at VRTX ( FY2018–FY2020). See the CEO track-record ranking for context.